Primary objective is to evaluate antihypertensive effect and safety of CS-3150 2.5 mg compared to Eplerenone in patients with essential hypertension.~Secondary objective is to evaluate antihypertensive effect and safety of CS-3150 5.0 mg compared to 2.5 mg.
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.